Which gastrointestinal side effects occurred in at least 10% of patients with Cushing’s disease treated with Signifor (pasireotide diaspartate)?

Diarrhoea, abdominal pain and nausea occurred in at least 10% of Cushing’s disease patients receiving Signifor (pasireotide diaspartate) in the phase III study; gastrointestinal reactions were usually low-grade, required no intervention and improved with continued treatment.